BIOMAT Database Logo BIOMAT Database Logo

Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. 1996

A de Gramont, and C Louvet, and M Bennamoun, and C Varette, and B Demuynck, and K Beerblock, and S Moreau, and D Soubrane, and F Mal, and J D Grangé, and D Zylberait, and M Krulik
Service de Médecine Interne-Oncologie, Hôpital Saint-Antoine, Paris, France.

Leucovorin and 5-fluorouracil (5-FU) can be further modulated with hydroxyurea. Sixty-eight patients with advanced colorectal cancer received every 2 weeks hydroxyurea per os 1.5 g to 2 g days -1, 1, and 2; leucovorin 200 mg/m2 iv over 2 hours started at least 1 hour after hydroxyurea and per os 100 mg/m2 12 hours later, on days 1 and 2; 5-FU, bolus 400 mg/m2 during leucovorin infusion and 24 hours continuous infusion 600 mg/m2, repeated on days 1 and 2. Two complete responses (7%), 8 partial responses (30%), 12 no change (44%), and 5 progressions (19%) were observed among 31 nonpreviously treated patients. Four partial response (11%), 15 no change (43%), and 16 progressions (46%) were observed among 37 pretreated patients. Nineteen were treated after progression on the same regimen without oral leucovorin and hydroxyurea, 1 achieved PR and 10 showed no change. Among them, 6 experienced response or stabilization of longer duration than with previous treatment. Twelve-month survival was 61% in non-pretreated and 43% in pretreated patients as of the start of chemotherapy. Toxicity was mild with nausea in 46%, diarrhea in 37%, and mucositis in 36%. The first-line response rate is in the range of leucovorin and 5-FU alone. Some pretreated patients benefited from this regimen.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006918 Hydroxyurea An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxycarbamid,Hydrea,Oncocarbide
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas

Related Publications

A de Gramont, and C Louvet, and M Bennamoun, and C Varette, and B Demuynck, and K Beerblock, and S Moreau, and D Soubrane, and F Mal, and J D Grangé, and D Zylberait, and M Krulik
5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer.
September 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A de Gramont, and C Louvet, and M Bennamoun, and C Varette, and B Demuynck, and K Beerblock, and S Moreau, and D Soubrane, and F Mal, and J D Grangé, and D Zylberait, and M Krulik
A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma.
August 1999, Annals of oncology : official journal of the European Society for Medical Oncology,
A de Gramont, and C Louvet, and M Bennamoun, and C Varette, and B Demuynck, and K Beerblock, and S Moreau, and D Soubrane, and F Mal, and J D Grangé, and D Zylberait, and M Krulik
Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid.
January 1992, European journal of cancer (Oxford, England : 1990),
A de Gramont, and C Louvet, and M Bennamoun, and C Varette, and B Demuynck, and K Beerblock, and S Moreau, and D Soubrane, and F Mal, and J D Grangé, and D Zylberait, and M Krulik
Preclinical and clinical evaluation of 5-fluorouracil biochemical modulation with folinic acid and hydroxyurea for patients with colorectal carcinoma.
October 1995, Cancer,
A de Gramont, and C Louvet, and M Bennamoun, and C Varette, and B Demuynck, and K Beerblock, and S Moreau, and D Soubrane, and F Mal, and J D Grangé, and D Zylberait, and M Krulik
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
January 2005, Oncology,
A de Gramont, and C Louvet, and M Bennamoun, and C Varette, and B Demuynck, and K Beerblock, and S Moreau, and D Soubrane, and F Mal, and J D Grangé, and D Zylberait, and M Krulik
A randomized trial of cimetidine with 5-fluorouracil and folinic acid in metastatic colorectal cancer.
October 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
A de Gramont, and C Louvet, and M Bennamoun, and C Varette, and B Demuynck, and K Beerblock, and S Moreau, and D Soubrane, and F Mal, and J D Grangé, and D Zylberait, and M Krulik
[Irinotecan plus fluorouracil and folinic acid in metastatic colorectal cancer].
June 2001, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
A de Gramont, and C Louvet, and M Bennamoun, and C Varette, and B Demuynck, and K Beerblock, and S Moreau, and D Soubrane, and F Mal, and J D Grangé, and D Zylberait, and M Krulik
Chronotherapy with 5-fluorouracil, oxaliplatin, and folinic acid in colorectal cancer.
November 1997, Lancet (London, England),
A de Gramont, and C Louvet, and M Bennamoun, and C Varette, and B Demuynck, and K Beerblock, and S Moreau, and D Soubrane, and F Mal, and J D Grangé, and D Zylberait, and M Krulik
Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study.
May 2003, Chemotherapy,
A de Gramont, and C Louvet, and M Bennamoun, and C Varette, and B Demuynck, and K Beerblock, and S Moreau, and D Soubrane, and F Mal, and J D Grangé, and D Zylberait, and M Krulik
[Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C].
January 1988, Onkologie,
Copied contents to your clipboard!